NovoSeven® RT helps more patient types than any other rFVIIa treatment.

See the Benefits

Rooted in effective bleed control.1

NovoSeven® RT helps more patient types than any other rFVIIa treatment.

See the Benefits

Learn more about how NovoSeven® RT helps your patients with:

Featured professional education.

Featured professional education.

See all

See all

Use our convenient dosing calculator.

With our dosing calculator, you can quickly determine the recommended NovoSeven® RT dose for your patient, plus the number of vials required.
 

Calculate a Dose

NovoSeven® RT with MixPro® offers rapid reconstitution.

Each vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluent—helping to save your patients’ valuable time.1,a

 

See How MixPro® Works

aCompared with reconstitution using histidine vials.

NovoSeven® RT with MixPro® offers rapid reconstitution.

Each vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluent—helping to save your patients’ valuable time.1,a

See How MixPro® Works

aCompared with reconstitution using histidine vials.

Education for your patients.

Education for your patients.

See all

See all

Support for your patients.

Novo Nordisk offers financial support to eligible patients.

View Our Support Programs

Available from Novo Nordisk:

Visit website | Prescribing Information

Visit website | Prescribing Information

Visit website | Prescribing Information

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia

 

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.
  • Exercise caution when administering NovoSeven® RT to patients with an increased risk of thromboembolic complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease, post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven® RT. Administer only if clearly needed in patients with known hypersensitivity to NovoSeven® RT, any of its components, or mouse, hamster, or bovine proteins. Should symptoms occur, discontinue NovoSeven® RT and administer appropriate treatment.
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis.

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia.

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII.

Please click here for Prescribing Information.  

 

Reference:

  1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2017.